Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07099534 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Ketamine Infusion for Symptomatic Improvement in Severe Borderline Personality Disorder

Study acronym: BorderKET
StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary and study completion dates: Dec 31, 2027 to Sep 30, 2028 Start date: Nov 1, 2025 to Sep 1, 2026v3 Show 1 more changeShow less
    • Start date: Nov 1, 2025 to Sep 1, 2026
  2. Study description revised Study title shortened, about 3 wordsv2 Show 1 more changeShow less
    • Study title shortened, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The main objective of this pilot study is to evaluate at D9 the evolution of BPD symptoms' intensity(scale BSL-23) in severe BPD patients, after two Ketamine infusions (0.5mg/kg at H0 and H24). The intervention is combined with the first level standard of care : Good Psychiatric Management (GPM). Patients are followed up to 3 months by regular visits conducted by a psychiatrist. Secondary outcomes are monitored including BPD symptoms at different times, suicidal ideation, depressiv symptoms, healthcare use and adverse effects.
Trial Details
NCT Number NCT07099534
Lead Sponsor University Hospital, Toulouse
Conditions Infusion of Ketamine in Severe Borderline Personality Disorder, Borderline Personality Disorder (BPD)
Enrollment 38 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov